For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
The CCTG SC28 SEAMLESS study is now open in Canada for anyone who has completed their primary cancer treatment, to learn mindfulness meditation on an app and see if it helps to improve stress and well being
"People who have had cancer may have multiple unmet psychosocial needs after the completion of their primary treatment, and for the first 5 years of surveillance and follow-up. Survivors often report feeling “lost in transition” as they shift back to their previous lives at home and in the workplace," says study chair Dr. Linda Ellen Carlson, Tom Baker Cancer Centre.
The CCTG HD12 trial is the second study in the RADAR international trial and has recently opened in Canada. Researchers will compare the usual treatment for Hodgkin lymphoma, with a new treatment that takes the standard combination drug treatment replacing one of the drugs with brentuximab vedotin that may be more effective and cause fewer side effects for patients.
CCTG is very happy to introduce our patient focused trial webpages that have been developed for recent CCTG trials open to patient enrollment. The goal for this content is to provide CCTG trial specific plain language information for patients and their families that can be used to enhance discussions with their health care team.
A new webpage has been created for members to access the most up-to-date ID.me information. You can now find the direct link to the ID.me updates on the CCTG website in the "Toolbox" under "Updates".
The new direct link can be found here: https://www.ctg.queensu.ca/private/member-updates/IDme if your team needs to bookmark the information.
